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Abstract  
INTRODUCTION: Myocardial infarction is a rare medical event in young people. The main reasons 
include congenital coronary abnormalities, coronary artery spasm, and coronary thrombosis due to 
hypercoagulable states (hereditary and acquired).  
AIM: We present a case of a young male adult with myocardial infarction caused by a combination 
of gene mutations and anticoagulation protein deficiency.  
CASE PRESENTATION: A 19 years old young man was admitted to our hospital complaining of 
chest pain during the last two weeks. The patient did not have any known cardiovascular risk 
factors, except a positive family anamnesis. Subacute inferior nonST segment myocardial infarction 
was diagnosed according to the patient’s history, electrocardiographic and laboratory findings. 
Coronary angiography revealed suboclusive thrombus in the proximal, medial and distal part of the 
right coronary artery (TIMI 2). Percutaneous coronary intervention was performed. Anticoagulant 
and antiagregant therapy (heparin, acetilsalicilic acid and clopidogrel) according to protocol was 
started. The hospital stay was uneventful. Homozygous endothelial nitric oxid synthase (eNOS) T-
786-C mutation, heterozygote prothrombin gene mutation (G-20210-A), and protein S deficiency 
were verified from the thrombophilia testing. Other trombophilic tests were normal. Three months 
after discharge from hospital another coronary angiography was performed. It revealed normal 
coronary arteries. Four years after the attack, the patient is free of symptoms and another 
cardiovascular event. 
CONCLUSION: Combination of genetic mutations and anticoagulation protein deficiency could be a 
reasonable cause for myocardial infarction in a very young male adult without any other 
cardiovascular risk factors. 
 
 
 
 
 
Introduction 
 
Acquired or hereditary hypercoagulability or 
thrombophilia may be defined as a tendency to 
venous or arterial thrombosis. Acquired 
hypercoagulability leading to arterial thrombosis is 
seen in every day surgical practice, while the genetic 
predisposition for development of arterial occlusive 
disease is still inconclusive. Past, as well as more 
recent publications suggest a correlation between the 
existence of particular genetic mutations and arterial 
thrombosis [1]. There is clear evidence that 
hyperhomocysteinaemia [2] and the antiphospholipid 
antibody syndrome
 
[3] are a genetic predisposition to 
arterial thrombosis, but the role of prothrombin gene 
G20210A variant mutation and the factor V Leiden 
deficit is still unclear [4]. It seems that genetic 
mutations are particularly important for young patients 
and women since the data suggest that they increase 
the risk of myocardial infarction and ischemic stroke 
[5, 6].
 
Three to ten percent of all myocardial 
infarctions of young people occur due to non 
atherosclerotic disease such as congenital coronary 
artery anomalies, myocardial bridging, coronary artery 
dissection, septic vegetations, coronary artery 
aneurysms, hypercoagulable states (hereditary and 
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acquired)
 
[7, 8]
 
and drug abuse.  
We present a case of a young adult with 
subacute myocardial infarction, without the traditional 
coronary artery disease risk factors, and with a 
combination of gene mutations and anticoagulant 
protein deficiency.  
 
 
Case Presentation 
 
A 19 year old young man was admitted to our 
hospital complaining of chest pain during the previous 
two weeks. He was not obese; he was an active 
athlete, and a nonsmoker. He does not consume 
alcohol regularly nor does he abuse drugs. The 
patient had no hypertension, hyperlipidemia or 
diabetes mellitus. He had no prior history of 
cardiovascular events. He has a positive family 
anamnesis for coronary artery disease. 
Electrocardiography showed sinus rhythm (HR 
55/min), normal cardiac axis, 2 mm Q waves in D3, 
AVF, T wave negative in D2, D3, AVF, no ST segment 
elevation. Transthoracic echocardiography revealed 
hypokinesia of the inferior wall with preserved systolic 
function of the left ventricle. Laboratory analysis 
showed increased levels of the cardiac enzymes: 
creatine kinase 411 U/L (32-211 U/L), creatine kinase 
MB 8.8 ng/ml (0-15 ng/ml), troponin 16 ng/ml (0.78 
ng/ml), and lactate dehydrogenase 947 U/l (208-378 
U/l). Subacute inferior nonST segment myocardial 
infarction was diagnosed according to the patient’s 
history, electrocardiographic and laboratory findings 
[9]. Coronary angiography was performed. It revealed 
subocclusive thrombus in the proximal, medial and 
distal part of the right coronary artery (TIMI 2) (Fig. 1).  
 
Figure 1: Coronary angiography. Sub occlusive thrombus in the 
proximal, medial and distal part of the right coronary artery (TIMI 2) 
The other coronary arteries had no stenosis. 
Anticoagulant and antiagregant therapy (heparin, 
acetilsalicilic acid and clopidogrel) was started 
according to protocol [9]. The hospital stay was 
uneventful. After discharge, blood was drawn 
according to the guidelines for thrombophilia tests and 
sent for thrombophilic testing.  
Homozygous endothelial nitric oxid synthase 
(eNOS) T-786C mutation, heterozygote prothrombin 
gene mutation (G-20210-A), and protein S deficiency 
were verified from the thrombophilia testing. Protein S 
deficiency activity was estimated at 10% (reference 
range 60-150%).  
Deficit of antithrombin III, protein C and 
presence of antiphospholipid antibodies were 
excluded. There were no genetic mutations for factor 
V Leiden, genetic variants of the beta fibrinogen gene, 
gene for PAI-1, polymorphism in human platelet 
antigen (HPA1) (1a/1a), MTHFR C677T gene 
mutation, high levels of apolipoprotein B and factor 
XIII.  
We recommended dual antiagregant therapy 
(acetilsalicilic acid a 100 mg plus clopidogrel a 75 mg 
per day) during one year after the myocardial 
infarction. After that, we recommended lifelong 
treatment with acetilsalicilic acid tablets.  
Another coronary angiography was performed 
three months after discharge from hospital. It revealed 
normal coronary arteries (Fig. 2).  
 
Figure 2: Coronary angiography. Normal flow through the right 
coronary artery 
 
During 4 years follow up the patient was 
asymptomatic, without another acute coronary event.  
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Discussion 
 
In our paper we present a case of a very 
young male patient with subacute myocardial 
infarction due to thrombosis of the right coronary 
artery. After excluding the conventional cardiovascular 
risk factors, thrombophilic tests were performed and 
revealed homozygous endothelial nitric oxid synthase 
(eNOS) T-786C mutation, heterozygote prothrombin 
gene mutation (G-20210-A), and protein S deficiency.  
Arterial thrombosis is a multi-factorial 
condition, where most of the risk factors do not 
overlap with those for venous thrombosis. An 
increased risk for arterial cardiovascular diseases by 
heritable thrombophilia could not be established 
firmly. The treatment and secondary prevention 
should relate to the established cardiovascular risk 
factors. Testing for heritable thrombophilia is not 
recommended, although there are many studies that 
confirm the coexistence between genetic mutation 
and arterial thrombosis.  
Nitric oxide is produced by endothelium and 
plays an important role as a smooth muscle relaxant 
in maintaining vascular tone as well as inhibiting 
activation and aggregation of platelets [10]. 
Endothelial nitric oxid synthase catalyses the 
synthesis of nitric oxide. Presence of a T-786-C 
mutation in the eNOS gene results in decreased 
synthesis of nitric oxide and confers a greater risk for 
coronary artery spasm [11], ulcerative lesions in 
internal carotid artery [12]. Homozygous endothelial 
nitric oxide synthase (eNOS) T-786-C mutation is 
known as an independed risk factor in combination 
with other known cardiovascular risk factors, such as 
cigarette smoking [13]. In addition to the clinical 
connection between eNOS T-786 mutation and risk 
for arterial thrombosis and atherosclerosis, there is 
molecular evidence for changes in markers of 
oxidative stress in high risk patients [14]. The 
presence of the T-786 gene mutation in our patient, 
without other cardiovascular risk factors, but in 
combination with other gene mutations, suggests that 
this gene mutation is a potential cause for arterial 
thrombosis in such a constellation.  
Prothrombin is a precursor of thrombin, acting 
as a pro-coagulant, via platelet activation and the 
generation of fibrin and factors Va, VIIIa, and XIIIa, 
and subsequently as an anticoagulant, by activating 
protein C. The prothrombin gene mutation is 
associated with elevated prothrombin levels, which is 
a genetically determined trait that increases the 
thrombosis risk [15]. About 1% to 2% of the general 
Caucasian population is heterozygous for the 
prothrombin gene which increases the risk of 
developing blood clots 2 to 5 times. Homozygous 
people have an even greater risk. Large number of 
studies demonstrated an association between the 
prothrombin G20210A mutation and venous 
thromboembolism. Recently, one study demonstrated 
a significant influence of prothrombin gene 
polymorphisms on myocardial perfusion [15]. The 
prothrombin G20210A mutation might play role in 
arterial thrombosis especially in young people [16] 
with other known cardiovascular risk factors.  
Protein S, a vitamin K dependent 
physiological anticoagulant, acts as a nonenzymatic 
cofactor to activated protein C in the proteolytic 
degradation of a factor Va and factor VIIIa. Protein S 
deficiency may be hereditary or acquired (due to 
hepatic disorders or a vitamin K deficiency). 
Hereditary protein S deficiency represents an 
autosomal dominant trait and manifestations of 
thrombosis are observed in both heterozygous and 
homozygous individuals. Protein S deficiency usually 
manifests clinically as venous thromboembolism and 
the absolute risk of thrombosis in patients with protein 
S deficiency has been estimated to be 8.5 times 
higher than in individuals with no defect [17]. There 
are studies that suggest an association between 
arterial thromboses (stroke, heart attack) in patients 
with protein S deficiency, but its role in arterial disease 
is still being explored [18]. In patients younger than 55 
years of age protein S deficiency should be 
considered as atherothrombotic risk factor [19].
 
 
Venous and arterial thromboses are complex 
genetic traits, with various gene-gene and gene-
environment interactions. A number of studies have 
evaluated and confirmed that the coinheritance of two 
or more defects increases the appearance of 
thrombosis [20].  
In spite of the fact that opinions about protein 
S deficiency and prothrombin G20210A mutation and 
their role in the appearance of arterial thrombosis are 
divided, the combination with other genetic defects 
like T-786-C mutation in the eNOS gene, may 
enhance the probability of arterial thrombosis like 
myocardial infarction, especially in young individuals 
without any other risk factors. In these clinical cases, 
testing for coagulation disorders should be performed 
in order to recommend a long term therapy which 
could prevent any other thrombotic events.  
In conclusion, the combination of genetic 
mutations and anticoagulation protein S deficiency 
could be a reasonable cause for myocardial infarction 
in a very young male adult without any other 
cardiovascular risk factors. This case suggests that in 
premature coronary artery disease thrombophilia tests 
are justified. In addition to its scientific value, genetic 
tests could be a solid basis for further therapy 
recommendation.  
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